NCT05697874 International Rare Brain Tumor Registry
| NCT ID | NCT05697874 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's National Research Institute |
| Condition | Astroblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,800 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2033-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,800 participants in total. It began in 2023-01-01 with a primary completion date of 2033-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.
Eligibility Criteria
Inclusion Criteria: * Patients with a known or suspected CNS Sarcoma. * Patients with a known or suspected BCOR-altered brain tumor * Patients with a known or suspected Astroblastoma/NM-1 altered brain tumor * Patients with known or suspected histologically ambiguous/unclassifiable brain tumor * Patients with a known or suspected rare brain tumor. * Signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study. Exclusion Criteria: * The patient has an extra-CNS primary tumor. * The patient is older than 46 years of age at diagnosis. * The patient or family is not willing to participate or does not sign informed consent.
Contact & Investigator
Adriana Fonseca, MD
PRINCIPAL INVESTIGATOR
afonsecash@childrensnational.org
Frequently Asked Questions
Who can join the NCT05697874 clinical trial?
This trial is open to participants of all sexes, up to 45 Years, studying Astroblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05697874 currently recruiting?
Yes, NCT05697874 is actively recruiting participants. Contact the research team at afonsecash@childrensnational.org for enrollment information.
Where is the NCT05697874 trial being conducted?
This trial is being conducted at Los Angeles, United States, San Francisco, United States, Washington D.C., United States, Chicago, United States and 6 additional locations.
Who is sponsoring the NCT05697874 clinical trial?
NCT05697874 is sponsored by Children's National Research Institute. The principal investigator is Adriana Fonseca, MD at afonsecash@childrensnational.org. The trial plans to enroll 5,800 participants.